SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended			9 Months Ended				1 Months Ended	3 Months Ended	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2009	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014 Protalix Bio Therapeutics Incorporation [Member]	Sep. 30, 2014 Pfizer Incorporation [Member]	Jun. 18, 2013 Protalix Ltd. [Member]	Dec. 31, 2009 Upon Filing of Pediatric Investigation Plan to EMA [Member]	Jun. 30, 2012 Upon FDA Approval [Member]
Significant Accounting Policies [Line Items]
Number of Subsidiaries				2
Pfizer Agreement, upfront payment received			$ 60.0						$ 5.0
Milestone payment triggered										25.0
Pfizer Agreement, future revenues and expense sharing percentage						40.00%	60.00%
Supply commitment for entitled rights to be received								280
License and supply agreement potential future payment								12.5
Supply agreement maximum consideration payment								40
Revenue from sale of products				$ 3.5
Common stock, par value per share	$ 0.001	$ 0.001		$ 0.001	$ 0.001
Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive	18,661,182	8,817,090		18,781,572	7,879,601